Ashwagandha — Expert Claims
Extracted from publicly available podcast transcripts and videos. Each claim is attributed and sourced.
Claims are extracted using AI (Claude) from publicly available transcripts and manually reviewed. Extraction confidence (high / medium / low) indicates accuracy of capture. Each claim is compared against PubMed research.
3 expert mentions
"Ashwagandha has some decent evidence behind it for reducing cortisol — the stress hormone. I've used it myself and I tend to take it in the evening because it has a somewhat sedating quality. The studies generally support a cortisol-lowering effect, though the magnitude varies."
Huberman describes ashwagandha as one of the more evidence-supported adaptogens for reducing cortisol and stress, and notes it can have a sedating quality that makes it better suited to evening use.
Huberman's characterization of ashwagandha having decent evidence for cortisol reduction is broadly accurate — the Chandrasekhar 2012 RCT and others show significant reductions in serum cortisol and perceived stress. His observation about sedating quality is consistent with the sleep trial data (Langade 2019). However, the phrase "decent evidence" appropriately hedges the moderate quality of individual trials, which are small and often use standardized extracts not representative of all products.
"Ashwagandha contains a class of compounds called withanolides, which appear to modulate the hypothalamic-pituitary-adrenal axis — that's the stress response system. There's some interesting animal work on neuroprotection, but we have to be cautious translating that to humans. The human trials on stress and cortisol are encouraging, even if they're not definitive."
Rhonda Patrick discusses the mechanistic basis of ashwagandha's adaptogenic effects, including withanolides modulating the HPA axis, and highlights animal data on neuroprotective properties while acknowledging the human evidence is still emerging.
The mechanistic description of withanolides and HPA axis modulation is consistent with preclinical literature. Animal data on neuroprotection exists, but translation to human outcomes is not established in large trials. Patrick appropriately flags the distinction between animal and human evidence, and her characterization of the human stress/cortisol data as "encouraging but not definitive" is a fair reading of the current literature.
"I'm not dismissive of ashwagandha — there are some reasonable trials showing cortisol reduction and stress effects. But I hold it at arm's length. The studies tend to be small, often industry-sponsored, and we don't have great long-term safety data. If someone is going to use it, I'd suggest cycling — maybe 8 to 12 weeks on, then a break."
Peter Attia expresses cautious interest in ashwagandha but notes the evidence base is modest, the trials are often small and funded by manufacturers, and he recommends cycling it rather than continuous long-term use.
Attia's caution is well-calibrated. Existing RCTs are predominantly small (n=50–100), relatively short (8–12 weeks), and in several cases conducted with manufacturer-provided extracts. Long-term (>6 months) safety data in humans is limited. Cycling is a reasonable precautionary approach that many practitioners advocate, particularly given limited data on thyroid hormone interactions with prolonged use.